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letter to the editorPersistence of both cords
nine months post double
cord blood transplantation
for juvenile
myelomonocytic
leukaemia
To the Editor: Single donor cord
dominance after double-cord
blood transplant (DCBT) is com-
mon.1 We report the case of a
2-year-old boy who had persis-
tence of both cords 9-months
post-DCBT done for juvenile
myelomonocytic leukaemia (JMML).
Both cord units were 4/6 match at
HLA loci with respect to the reci-
pient and 6/6 with each other (Ta-
ble 1). The combined CD34 cell
count of the grafts was
2.69 · 105/kg of recipient body
weight. The cords were infusedTable 1. Baseline characteristics of the patient a
Sex Patient
Male
Blood Group A positive
HLA A*11 A*26, B*08 B*35, DRB1*
DRB1*15:02:01
Viable NCa
count
(X 107)/kg
Weight 10.9 kg
Viability (%) –
aTotal nucleated cell dose.
Table 2. Serial monitoring of post-transplant engr
In-situ Hybridization (FISH, using Vysis DNA prob
Post-transplant day
Day +20 55% X
Day +31 56% X
Day +58 N
Day +82 N
Day +268 N
Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2intravenously in a sequential man-
ner post myeloablative condition-
ing with busulphan (16 mg/kg),
cyclophosphamide (120 mg/kg)
and melphalan (140 mg/m2).
Graft-versus-host disease
(GVHD) prophylaxis comprised
ATG, cyclosporine and predniso-
lone. Neutrophil and platelet
engraftment occurred on days
+15 and 49 post-transplant
respectively. The patient developed
grade-III acute skin and gut
GVHD which responded to pred-
nisolone 2 mg/kg/day and topical
medications. This later evolved
into chronic skin rash and diar-
rhoea which were managed with
local and systemic steroids and
imatinib mesylate. Patient also
had cytomegalovirus reactivation
which was resistant to ganciclovirnd two unrelated cords.
Cord 1
Male
B positive
15:02:01 A*11 A*26, B*08 B*35, DRB1*15:0
DRB1*13:01:01
7.1
93.84
aftment status assessment by chimerism studies (u
es).
FISH Chimerism studies
Y + 45% XX 50% Cord 1 + 50% Co
Y + 44% XX Not done
ot done 52% Cord 1 + 48% Co
ot done 65% Cord 1 + 35% Co
ot done 64% Cord 1 + 36% Co
013but responded well to intravenous
foscarnet. His blood group chan-
ged to that of donor cord 2 initially
and later to cord 1 (Table 2). The
peripheral blood chimerism
showed persistence of both units
on day +268. The results of his
engraftment studies are shown in
Fig 1. Gradually his oral steroids
could be tapered off by day
+180. However, the patient con-
tinued on cyclosporine and oral
budesonide. Presently, the child is
300 days post-transplant with sus-
tained remission and donor stem
cell engraftment with mixed chi-
merism (64% cord-1 and 36%
cord-2). However, he has devel-
oped acute skin and gut GVHD
features again and has required
reintroduction of steroids.Cord 2
Female
O positive
6 A*11 A*26, B*08 B*35, DRB1*15:06
DRB1*13:01:01
6.4
90.66
sing QF-STR multiplex assay) and Fluorescence
Patient blood group
rd 2 A positive
A positive
rd 2 O positive
rd 2 O positive
rd 2 B positive
79
Figure 1. Graph showing persistence of both cords on chimerism studies post double cord blood transplant (percentage).
80
letter to the editorThere is paucity of data on
DCBT in children with JMML.
Kang et al performed DCBT in
61 children with leukaemia and
other haematological and meta-
bolic disorders of which three pa-
tients were JMML.2 Two out of
these three patients had spontane-
ous autologous recovery.
It has been observed that after a
period of transient engraftment of
both cords in DCBT, one cord
may become dominant which may
be as early as d+21 post-trans-
plant. In a study by Milano et al,
out of 46 patients undergoing
myeloablative DCBT all except
one patient had complete contri-
bution from a single unit (as de-
ﬁned 95% chimerism), at a
median time of 14 days (IQR,
14-21 days). The only patient with
persistent contribution from both
units, still present at one year post
transplantation, received a treosul-
fan-based conditioning regimen
and 2 6/6 HLA-matched units.1
Factors which lead to dominance
of one cord are not completely
understood. It is postulated that
the cord units with higher cell via-
bility (>75%) are more likely to
engraft.3 Other authors have pro-
posed that the difference of viable
cell count between the two cord
units of more than 15% is associ-
ated with better engraftment sec-
ondary to immunological
interaction between the two units.2Most authors report single unit
dominance but sustained mixed
chimerism as in our case is also
known to occur.1,2 Avery et al ana-
lysed the biology of engraftment in
84 DCBTs and found that factors
predictive of dominance were a
higher CD 34+ and CD 3+ cell
dose4 similar to a study of Milano
et al.1 HLA mismatch between the
cord units was not found to inﬂu-
ence sustained engraftment. How-
ever, if both cords are a 6/6
match to each other as in our case
or one in the series of Milano et
al.1, then mixed chimerism is
highly likely. A potential advantage
of DCBT is a lower relapse rate
owing to greater graft versus leu-
kaemia effect5 but GVHD may
be a signiﬁcant adverse effect as
seen in our patient who continues
to have diarrhoea.
Although dominant cord
engraftment post DCBT is com-
mon, it is not, however, a rule.
Persistence of both cord units is
more likely if these are a 6/6
match to each other and may lead
to delayed acute GVHD.
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